Compounds > hevizos
Page last updated: 2024-12-08

hevizos

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID512735
CHEMBL ID2104604
CHEBI ID135111
SCHEMBL ID510260
MeSH IDM0140144

Synonyms (28)

Synonym
60136-25-6
1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-isopropyl-1h-pyrimidine-2,4-dione
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-isopropyl-pyrimidine-2,4-dione
epervudine [inn]
epervudine
CHEBI:135111
hevizos (tn)
D07899
epervudine (inn)
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propan-2-ylpyrimidine-2,4-dione
CHEMBL2104604
hevizos
epervudina
unii-3g05ph9fas
3g05ph9fas ,
epervudinum [inn-latin]
epervudina [inn-spanish]
epervudinum
5-isopropyl-2'-deoxyuridine
2'-deoxy-5-isopropyluridine
ip5-du
.beta.-5-isopropyl-2'-deoxyuridine
epervudine [who-dd]
SCHEMBL510260
DTXSID50208877
134785-30-1
Q27257170
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The blood level curves were analyzed by appropriate pharmacokinetic models."( [Pharmacokinetic studies of 14C-labeled epervudine in rats].
Dereszlay, I; Vereczkey, L, 1993)		0.29
" administration can be characterized by a two-compartment open pharmacokinetic model."( [Pharmacokinetic studies of epervudine in rats using HPLC].
Csárdi, A; Dereszlay, I; Mészáros, S; Pátfalusi, M; Vereczkey, L, 1993)		0.29

Bioavailability

ExcerptReferenceRelevance
" The ratio of areas under serum level curves following oral and intravenous administration proves a good bioavailability (90%) of Epervudine."( [Pharmacokinetic studies of epervudine in rats using HPLC].
Csárdi, A; Dereszlay, I; Mészáros, S; Pátfalusi, M; Vereczkey, L, 1993)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID96639Compound was tested for Cytostatic activity against proliferation of L1210/0 cells (murine leukemia L1210 cell line)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID84766Antiviral activity against Herpes Simplex Virus-2(Lyons)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID165780Compound was tested for Cytostatic activity against proliferation of Raji/0 cells (human lymphoblast Raji cells line)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID218133Antiviral activity against vaccinia virus1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID85715Antiviral activity against Herpes Simplex Virus-1(F)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID216540Antiviral activity against vesicular stomatitis virus1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID165782Compound was tested for Cytostatic activity against proliferation of Raji/TK cells (thymidine kinase deficient Raji cell line)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID84763Antiviral activity against Herpes Simplex Virus-2(196)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID85717Antiviral activity against Herpes Simplex Virus-1 (McIntyre)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID84765Antiviral activity against Herpes Simplex Virus-2(G)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID96641Compound was tested for Cytostatic activity against proliferation of L1210/BdU cells (thymidine kinase deficient L1210 cell line)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
AID85716Antiviral activity against Herpes Simplex Virus-1(KOS)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (15.38)18.7374
1990's11 (84.62)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.88 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uridine
[no description available]		1.9810uridinesdrug metabolite;
fundamental metabolite;
human metabolite
deoxyuridine
[no description available]		5.8122pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
edoxudin
[no description available]		1.9610pyrimidine 2'-deoxyribonucleoside
5-propyl-2'-deoxyuridine
5-propyl-2'-deoxyuridine: RN given refers to parent cpd		1.9610
brivudine
brivudine: anti-herpes agent		1.9610
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		3.37112-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9610
Cold Sore
[description not available]		04.3322
Herpes Simplex Virus Infection
[description not available]		03.7721
Herpes Labialis
Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.)		04.3322
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		03.7721
Genital Herpes
[description not available]		08.7721
Complications, Infectious Pregnancy
[description not available]		01.9810
Herpes Genitalis
Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.		03.7721
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9810
Shingles
[description not available]		03.3711
Herpes Zoster
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)		03.3711
B Virus Infection
[description not available]		01.9810